JAMA Surg: Warm chemotherapy in the abdominal cavity can improve the survival rate of patients with peritina false mucus tumor after surgery

Peritina false mucus tumor (PMP) is a low-level malignant mucus tumor that occurs in the abdominal wall layer, large retina and intestinal wall plasma surface, the incidence rate is low, mainly manifested in abdominal circumference increase with bloating, surgical treatment, rarely metastasis, but difficult to cure, easy to relapse, recurrence of poor prognosis.
in-abdominal thermothermal chemotherapy (HIPEC) has some effect in controlling the spread of free cancer cells in the abdominal cavity after gastric cancer surgery.
researchers recently examined the effects of HIPEC on the prognosis of patients with peritometrious mucus tumors.
study analyzed PSOGI cohort data, including 1924 patients with appendicular mucus cystic PMP who were randomly treated or controlled by HIPEC on the basis of tumor cell reduction (CRS), and the HIPEC group treatment options included oxali-fluorouracil-follyic acid, cisplatin-fissamycin, and filamentmycin-Osaliplatin.
of the study included total survival, serious complications, secondary surgery, and 30- and 90-day mortality.
1924 patients were studied, of whom 51.8% were men, with an average age of 56, 376 were treated with CRS alone, and 1,548 were treated in a joint CRS-HIPEC.
patients treated only with CRS were older (average age: 60 vs 54 years), had less lymph nodes (14 cases , 3.7 per cent) vs 119 cases (7.7 per cent), and had previously received a higher rate of preoperative systemic chemotherapy (7.7 per cent) 198 cases (52.7 per cent) vs 529 cases (34.2 per cent)), with a high proportion of oncology classification (179 cases (47.6 per cent) vs 492 cases (31.8 per cent).
HIPEC does not increase the risk of surgery other than fissamycin treatment, but the risk of postoperative complications is higher (HR=1.99).
in all sub-groups, the overall survival rate after HIPEC treatment was significantly improved (correcting the risk ratio of .HRs, 0.60-0.68).
the five-year weighted total survival rate of the CRS-HIPEC group was 57.8%, while the CRS treatment group alone was 46.2% (weighted HR:0.65), of which the HIPC scheme was most effective with oxalipari-fluorouracil-folate (HR:0.42) and cisplatin-fissamycin (HR:0.57).
study, for patients with peritina false mucus tumor, intracellular thermothermal chemotherapy after tumor cell reduction surgery can significantly improve the survival rate of patients.